Table 4 Clinical studies in Lung Cancer
From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer
| Patients | Trial, ID | Follow-up | Outcomes | Reference |
|---|---|---|---|---|
| Advanced NSCLC |
Phase 1b NCT02000947 | 24 weeks |
ORR, 23% Grade 3-4 AEs, 35% | Antonia et al 2016 |
| Treatment relapsed advanced SCLC |
Phase 1/2 NCT01928394 | ≥ 12 weeks |
ORR, 23% Median OS, 7.7 months 1-year OS rate, 43% Median PFS, 2.6 months 1-year PFS rate, 19% Grade 3-4 AEs, 30% | Antonia et al 2016 |
| Untreated advanced NSCLC | Phase 1 NCT01454102 | > 9 months |
ORR, 47% Median PFS, 8.1 months 24-week PFS rate, 68% Grade 3-4 AEs, 37% | Hellman et al 2017 |
| Untreated advanced NSCLC |
Phase 2 NCT02659059 | ≥ 6 months |
In patients with TMB≥10 mutations/megabase ORR, 44% Median PFS, 7.1 months 6-month PFS rate, 55% Grade 3-4 AEs, 29% (all patients) | Ready et al 2019 |
| Untreated advanced NSCLC |
Phase 3 NCT02477826 | > 11 months |
In patients with TMB≥10 mutations/megabase ORR, 45% Median PFS, 7.2 months 12-month PFS rate, 43% HR for disease progression or death, 0.58 Grade 3-4 AEs, 31% | Hellman et al 2018 |